Orforglipron Added to Titrated Insulin Glargine in Type 2 Diabetes

What is the efficacy and safety of once-daily oral orforglipron vs placebo when added to titrated insulin glargine in adults with inadequately controlled type 2 diabetes?In this randomized clinical trial including 546 participants, the mean change in hemoglobin A at 40 weeks was −1.58% with orforglipron, 3 mg once daily, −1.88% with orforglipron, 12 mg once daily, −1.82% with orforglipron, 36 mg once daily, and −0.79% with placebo. Each dosage of orforglipron was superior to placebo and did not increase hypoglycemia risk.Orforglipron improved glycemic control compared with placebo when added to titrated basal insulin in adults with type 2 diabetes.

Corresponding Author: Francesco Giorgino, MD, Department of Regenerative and Precision Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology, and Metabolic Diseases, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy (francesco.giorgino@uniba.it).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.